streptokinase n.【生物化學】鏈激酶。
n. 【生物化學】鏈激酶。 “streptodornase-streptokinase“ 中文翻譯： 鏈球菌dna酶-鏈激酶,鏈道酶-鏈激酶“streptokinase (sk)“ 中文翻譯： 鏈球菌激酶“streptokinase injection“ 中文翻譯： 鏈激酶注射液“streptokinase measurement“ 中文翻譯： 鏈激酶測量“streptokinase preparation“ 中文翻譯： 鏈激酶制劑“streptokinase titer“ 中文翻譯： 鏈球菌激酶效價“streptokinase,sk“ 中文翻譯： 鏈激酶“streptokinase-stroptodornase“ 中文翻譯： 雙鏈酶“recombinant streptokinase for injection“ 中文翻譯： 藥品商品名〗注射用重組鏈激酶“recombinant streptokinase，rsk“ 中文翻譯： 重組鏈激酶“streptokinase antibody measurement“ 中文翻譯： 鏈球菌激酶抗體測量“streptokinase-streptodornase reaction“ 中文翻譯： 鏈激酶-鏈道酶反應“streptograptus“ 中文翻譯： 卷筆石“streptogramins“ 中文翻譯： 為鏈陽性菌素類“streptogramin“ 中文翻譯： 鏈霉殺陽菌素; 鏈陽性菌素“streptognathodus“ 中文翻譯： 卷顎牙形石屬“streptogenin“ 中文翻譯： 蛋白促生長肽; 鏈霉配基; 鏈球菌促長肽; 助生長物質
streptomyces |
|
They can convert plasminogen into plasmin and thus degrade fibrin . despite the widespread use of established thrombolytic agents such as streptokinase , t - pa and u - pa , all these agents suffer from a number of inadequacies including resistance to reperfusion , occurrence of coronary reocclusion and bleeding complications 一些pa突變體及新型溶栓劑，如k2p tnk - pa和star等的臨床實驗結果表明它們在延長體內半壽期增強對血纖維蛋白選擇性和溶栓效率等方面有較大的改進。 |
|
All the currently used thrombolytic agents are plasminogen activators , which are very efficient in restoring the blood flow . they can convert plasminogen into plasmin and thus degrade fibrin . despite the widespread use of established thrombolytic agents such as streptokinase , t - pa and u - pa , all these agents suffer from a number of inadequacies including resistance to reperfusion , occurrence of coronary reocclusion and bleeding complications 介紹了國內外溶栓劑蛋白質工程方面的新進展，主要涉及了組織型纖溶酶原激活劑t - pa尿激酶型纖溶酶原激活劑u - pa鏈激酶sk葡萄球菌激酶sak dspa及tsv - pa的研究進展。 |
|
The quest continues for plasminogen activators with higher potency , specific thrombolytic activity , fibrin selectivity and longer half - life time . the recent progress in the protein engineering of plasminogen activators , including t - pa , u - pa , streptokinase , staphylokinase and other novel plasminogen activators , was presented in this article 一些pa突變體及新型溶栓劑，如k2p tnk - pa和star等的臨床實驗結果表明它們在延長體內半壽期增強對血纖維蛋白選擇性和溶栓效率等方面有較大的改進。 |
|
The systemic administration of heparin , warfarin or streptokinase is determined to have a thrombolytic effect but risk systemic or ocular bleeding and appeare to be unhelpul for improving visual acuity 全身應用肝素、華法令或鏈激酶溶栓藥物已被證實對提高視力沒有明確幫助，并且存在全身或局部出血的風險。 |
|
Conclusions the intrapleural administration of streptokinase does not improve mortality , the rate of surgery , or the length of the hospital stay among patients with pleural infection 結論在胸膜感染的病人中，鏈激酶胸膜腔內給藥不能改善死亡率、手術率或住院時間的長短。 |
|
The comparison of the repass rate between homemade recombined streptokinase and urokinase in thrombolytic therapy of acute myocardial infarction 國產重組鏈激酶與尿激酶在急性心肌梗死溶栓中的血管再通率的比較 |
|
Intrapleural streptokinase for pleural infection a step forward in managing pleural effusions 胸膜腔內滴注鏈激酶治療胸膜腔感染這是胸膜腔積液治療的進步嗎 |
|
Therapeutic efficacy of recombinant streptokinase and urokinase in the treatment of acute myocardial infarction 重組鏈激酶與尿激酶治療急性心肌梗死的療效 |
|
We conducted a trial to clarify the therapeutic role of intrapleural streptokinase 我們進行了一項試驗，以闡明胸膜腔內應用鏈激酶的治療作用。 |
|
Comparison of therapy with recombinant streptokinase and urokinase for acute myocardial infarction 尿激酶溶栓治療急性心肌梗死的對比研究 |
|
Comparison the effects of recombinant streptokinase and urokinase in acute myocardial infarction 尿激酶對急性心肌梗死溶栓的療效分析 |